Hereditary angioedema (HAE), caused by inherited deficiency of C1 esterase inhibitor (C1-INH), is characterized by recurring subcutaneous and/or submucosal edema.
symptoms are considered to be caused by genetic mutations of factor XII, plasminogen, 4 or angiopoietin-1. 5 As such, diagnosis/treatment remains a challenge. 6 HAE is characterized by recurrent episodes of localized subcutaneous (SC) or submucosal edema lasting for 2-5 days that occurs primarily in the extremities, face, genitals, trunk, and abdomen. 7 Laryngeal edema (approximately 1% of all HAE type I and II attacks) may occur at any time and is potentially lifethreatening. [7] [8] [9] Numerous treatment options are available for HAE; these include on-demand treatment options for management of acute attacks (eg, ]) and long-/short-term prophylactic treatment to reduce the frequency and/or severity of HAE attacks, for example, C1-INH replacement therapy, attenuated androgens, 13 and antifibrinolytics 14 ( Figure 1 ). C1-INH has demonstrated considerable efficacy and safety, and while androgens may be effective in some patients, they are associated with side effects, particularly in women and children. 15 Table 1 shows the different treatment options that are used in Japan as recommended by the Japanese Association for Complement Research. Three options are used for on-demand and prophylactic treatment; the antifibrinolytic tranexamic acid (TXA), C1-INH replacement therapy, and the attenuated androgen, danazol. 16, 17 Of these, plasma-derived (pd) C1-INH is specifically licensed for the treatment of HAE, 18 while TXA is licensed for urticaria and swelling, not necessarily caused by HAE. 19 Tranexamic acid was first reported by Okamoto and Okamoto in Japan, who highlighted its potent inhibitory effects on fibrinolysis. 20 A synthetic derivative of lysine, TXA works by binding to plasminogen molecules. This in turn inhibits the formation of plasmin, which is normally inhibited by C1-INH. As such, TXA blocks the activation of the complement system and immune cells such as neutrophils, thus attenuating the symptoms of HAE. 21 TXA can be administered orally or intravenously 19 and is utilized in the management of perioperative bleeding, 22 trauma, 23 and also in the treatment of melasma. 24 Although TXA is generally well tolerated with a low adverse event rate, there are concerns regarding lack of efficacy compared with other widely available treatment options, that is, C1-INH replacement therapy and attenuated androgens. 25 Moreover, many patients continue to experience intermittent swellings and require additional use of rescue medication while on TXA prophylaxis. 26 Importantly, clinical data have failed to demonstrate a dose of antifibrinolytics that is effective in a large number of patients, and furthermore, side effects including nausea, fatigue, and diarrhea have been observed in some observational studies. 27 The therapeutic efficacy of TXA is determined on an individual basis, and each patient should be treated with the lowest effective dose.
A retrospective survey in Japan found that TXA was used for prophylaxis in 39.2% of patients. 28 This is a nontypical situation compared with many other regions and is due to limited availability of HAE-specific therapies. Furthermore, self-administration of pdC1-INH is not licensed in Japan, and not all hospitals keep adequate stocks, which can make accessibility difficult for some patients. 29 Importantly, TXA is a more suitable option for patients in whom androgens are contraindicated, for example, women and expectant mothers. 15 In addition, androgens have been associated with numerous anabolic/androgenic side effects; therefore, treatment requires careful monitoring of patients for the detection of adverse events. significantly reduced symptom severity compared with placebo. 31, 32 In addition, the long-term safety and efficacy of pdC1-INH have been evaluated using real-world patient registry data, which showed that pdC1-INH administration reduces the rate of attacks and is associated with an excellent safety profile. 33 Recently, SC injection of C1-INH has also been approved for long-term prophylaxis (LTP) in adults and adolescents. Data from the COMPACT trial demonstrated a favorable safety profile and a significantly reduced rate of attacks with self-administered SC C1-INH, which also resulted in near-normal C1-INH levels. 34 Given the advent of numerous effective therapies in recent years, the aim of this systematic review was to analyze the evidence for the use of TXA as an on-demand and/or prophylactic treatment option in patients with HAE. The efficacy of TXA for the treatment of HAE was assessed through the evaluation of safety and efficacy data from clinical trials, observational studies, and case reports.
| ME TH ODS

| Search strategy
This review was constructed based on two research questions: (a) Does the evidence suggest that TXA is an effective strategy for the prophylactic/on-demand treatment of HAE? and (b) Should TXA continue to be used even though newer and more effective therapies are available? Searches were performed using PubMed to identify published clinical data from inception to May 10, 2018 . The following search terms were used: "hereditary angioedema" OR "hereditary angio-neurotic edema" AND "tranexamic acid." The main searches were complemented by searching the Cochrane Library; however, no additional studies were identified.
Searches were also performed on Embase to identify additional studies not found in PubMed.
| Selection of studies
Titles and abstracts of all retrieved articles were assessed to identify eligible studies. Relevance was defined according to inclusion and exclusion criteria listed in Table 2 . Eligible studies were published in English, conducted in human subjects, and contained original clinical data on the efficacy or safety of TXA in type I/type II HAE. Narrative and systematic review articles were not included. Titles and abstracts were initially screened followed by full-text analysis in cases of uncertainty.
| Data extraction and assessment
The following data were extracted: type of study, patient population, efficacy outcomes, for example, prevention of attacks or alleviation of symptoms, and safety outcomes, for example, adverse reactions or side effects. All retained articles underwent grading and bias assessment using the "SIGN" grading system; the quality of studies was determined following assessment of study design and methodology 35 (Table S1 ). (Table S1 ).
Using this system, RCTs were given a score of 1 (the highest rating), whereas case reports were given a score of 3 (the lowest rating). All other articles, including observational studies, were given a score of 2. Studies were further up or downgraded based on the robustness of the study design, whereby ++, +, or -was added, to denote low, acceptable, or high risk of bias, respectively. The evidence base for this review was formed mainly of case reports/series (N = 16) [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] and observational studies (N = 10). [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] There was one RCT, 62 two crossover studies, 63, 64 one questionnaire, 65 and one survey. 66 Three studies evaluated 
| RESULTS
| Included Studies
| Bias Assessment
Two studies were assigned a grading of 1, indicating a weak-to-moderate evidence base overall. Several of the included studies were case reports with no valid comparator; these reports were assigned a quality grading of 3 and did not undergo bias assessment (N = 16).
The majority of the observational studies were assigned a grading of 2+, meaning that they were deemed to have an acceptable risk of bias, apart from three studies. 53, 60, 61 One randomized crossover study was assigned a grading of 1−, 63 while the other nonrandomized crossover study was assigned a grading of 2-. 64 A single RCT was graded as 1+, with an acceptable risk of bias overall despite industry sponsorship. All observational studies are at risk of reporting bias as there is no control of confounding variables, and observed effects cannot be conclusively attributed to therapeutic interventions. Selection bias was identified in 80% of studies that underwent bias assessment; this was largely due to the absence of defined inclusion/exclusion criteria. Recall bias was identified in 40%, including studies that relied on patient-reported data. Detection bias due to small sample size was identified in 87% of the studies included in the assessment. Industry involvement was identified in 27% (Table S1 ).
| Efficacy of tranexamic acid for on-demand treatment
Studies assessing the efficacy of TXA for on-demand treatment of HAE attacks are listed in Table 3 . The corresponding SIGN level is also shown; there was one RCT, two observational studies, one questionnaire, and one case series. Overall, the evidence base for on-demand treatment was moderate-low; the majority of studies
were assigned a quality grading of 2, and all studies demonstrated that TXA was effective in a subpopulation of patients and was less effective than other on-demand treatments.
The strongest evidence for the reduced efficacy of TXA comes from a single RCT in 74 patients; the study by Cicardi et al 62 demonstrated that icatibant was significantly more effective than TXA in treating acute HAE attacks. The median time to clinically significant relief of symptoms was 2 and 12 hours for icatibant and TXA, respectively. Further, the percentage of patients with clinically significant relief of symptoms at 4 hours after the start of treatment was 80% in the icatibant group, compared with 31% in the tranexamic acid group (both P < 0.001).
62
In a more recent study of on-demand TXA treatment, Nordenfelt et al 65 used a patient questionnaire to analyze the efficacy of a number of treatments, including C1-INH, androgens, and TXA. Participants were asked to grade the efficacy of treatment on a 4-step scale, 0 being no effect and 3 being very good. Although data were based on patient-reported outcomes, TXA was graded 1 for skin 
swellings, indicating poor efficacy, and was ineffective for abdominal and laryngeal attacks. In addition, androgens had poor efficacy while C1-INH had a more positive effect and better grading overall. Two observational studies also showed that newer therapies were significantly more effective than TXA for the treatment of HAE attacks.
Zanichelli et al 61 reported that pdC1-INH significantly improved attack duration compared with TXA (median duration of attacks:
1.10 days pdC1-INH; 1.79 days TXA; P < 0.01). Importantly, the median duration of attacks was not significantly different compared with those that received no treatment (1.79 vs 1.85 days, respectively; P > 0.05). The results of this study were echoed by Zanichelli et al 60 ; the median duration of attacks following icatibant (8 hours) or pdC1-INH (11.5 hours) treatment was significantly lower compared with TXA (38 hours) or untreated patients (45 hours). In contrast, a case series by Ohela et al 46 found that TXA had a beneficial effect in six out of seven patients that were treated on-demand.
| Efficacy of tranexamic acid for prophylaxis
Studies assessing the efficacy of prophylactic treatment with TXA for prevention of HAE attacks are shown in Tables 4 and 5 along with the corresponding SIGN level. A total of 24 studies assessed the efficacy of TXA for LTP in patients with HAE; of these, 14 (58%)
reported some positive effects of TXA (Table 4 ). There were 10 case reports and four case series, seven observational studies, two crossover studies, and one survey. The evidence base for prophylactic use of TXA is moderate-weak. Although there were several studies demonstrating a beneficial effect of prophylactic treatment with TXA, the majority of studies were deemed to be low-level evidence and assigned a SIGN grade of 2 or 3. Our study identified ten reports (42%) demonstrating that TXA was ineffective or led to worse outcomes following long-term prophylactic treatment in patients with HAE. Figure 3 shows the proportion of case reports, case series, and observational studies that reported better/worse outcomes or no change in response to TXA LTP. The most robust data were reported in a randomized crossover study; Blohme et al 63 found that 3/5 patients responded positively to TXA prophylaxis compared with placebo.
| Long-term prophylaxis
One patient experienced abdominal pains and skin edema for the duration of treatment, and TXA had to be withdrawn due to severe vomiting. Another nonrandomized crossover study showed that TXA led to a complete or almost complete cessation of attacks in 7/18 patients (39%), 64 and TXA modestly reduced the frequency of attacks in four patients; however, these attacks were of markedly reduced severity. showed that TXA prophylaxis resulted in increased attack frequency, 50 adverse effects leading to discontinuation, 48 and recurrent laryngeal edema. 42 
| Beneficial outcomes following TXA treatment
| Short-term prophylaxis (STP)
Four studies looked at the use of TXA in STP ( 
| Safety profile of TXA
Many studies failed to report any safety data (15/31, 48%; Tables 3-5) .
Reported side effects in response to on-demand TXA treatment included fatigue and dizziness in a limited number of patients. Most of the trials that reported safety data in response to TXA LTP did not identify any adverse events; however, abdominal discomfort, vomiting, pruritus, vertigo, and diarrhea were reported in some patients.
| DISCUSSION
This systematic review evaluated data on the use of TXA for on-demand (N = 5) and prophylactic treatment (N = 28) of HAE caused by C1-INH deficiency. We found that there is limited evidence for the use of TXA as an on-demand treatment and that it is generally inferior to other treatments such as pdC1-INH and icatibant. The evidence for the use of TXA in prophylaxis varied; for long-term prophylaxis, thirteen studies demonstrated some TXA efficacy, that is, reduced attack frequency and/or severity; however, these data are contradicted by studies demonstrating that TXA was ineffective in some patients and was less effective than other treatment such as C1-INH. Importantly, these data also came from small, noncontrolled studies. For short-term prophylaxis, TXA was largely used successfully during dental procedures or perioperatively to prevent acute attacks; however, larger, controlled trials are necessary to This review demonstrates that there is very limited data on the efficacy of TXA as an on-demand treatment. Only a single RCT was identified, and results from this study showed that TXA took six times longer to induce clinically significant relief of symptoms compared with icatibant. 62 These data were supported by evidence from observational studies. 60, 61 Guidelines also state that either pdC1-INH (first-line) or androgens (second-line) should be used for LTP. 67 Similarly for STP, the guidelines do not make a specific recommendation for TXA use, stating that its efficacy in suppressing breakthrough attacks seems to be low. 67 The conflicting evidence generated by observational studies and case reports highlights the difficulty in drawing firm conclusions regarding the efficacy of TXA.
While there were several observational studies and case reports supporting the lack of efficacy of TXA for prophylaxis, we also identified some studies demonstrating that TXA may be effective in some patients. Gomez-Traseira et al 56 found that patients receiving TXA experienced fewer attacks than those on C1-INH. Importantly, C1-INH was administered to patients with more severe disease.
Reduction in the frequency of attacks as a measurement of response may provide more valuable data, as this is not affected by differences in the baseline frequency of attacks between patients on different treatments.
A previous systematic review on the management of HAE concluded that more comparative trials are required to provide convincing evidence of the benefit and safety of specific, potentially lifelong prophylactic therapy, including antifibrinolytics. 69 However, since publication of this report in 2012 no new RCTs have been conducted.
TXA may be particularly useful for STP during tooth extraction and uncomplicated surgical procedures, as the majority of studies showed that perioperative TXA prophylaxis provided adequate protection from attacks. Importantly, there is consensus that treatment should be individualized to each patient; therefore, for a limited number of patients who may benefit, TXA use is advocated. 68 On the whole, there are insufficient safety data on TXA in HAE.
Somewhat outdated preclinical data suggested that long-term TXA administration at high doses led to tumor formation in the retina and liver, 70 while regulatory bodies state that TXA can be associated with vomiting, diarrhea, and hypersensitivity, and should not be used in patients with renal insufficiency. 14, 71, 72 However, the findings of this review suggest that overall, TXA is generally well tolerated and based on equivalent efficacy is preferable to androgens. Importantly, as most of the safety data have been generated from case reports on individual patients, it is difficult to generalize these results to all patients with HAE, and to properly assess the safety of tranexamic acid, more robust clinical trials are required as well as long-term, real-world evidence.
| CONCLUSION S
In certain countries, particularly Japan, TXA is an important treatment option for many patients with HAE, particularly for LTP.
Although C1-INH has been demonstrated to be safe and In addition, awareness of HAE among physicians in Japan is low and the limited availability of effective therapies increases the burden of HAE. 73 Diagnosis of HAE worldwide can take an average of 8.3 years; this figure is thought to be much longer in Japan. 29, 73, 74 While danazol is available for off-label use, it has been associated with numerous side effects, including virilization, headaches, depression, and acne. In addition, the risk of adverse events in response to androgens increases the longer the duration of treatment. 15 Our findings suggest the need for increased awareness of available treatment options and an increase in the availability of more effective options to allow Japanese HAE patients to access the best available therapies. Published guidelines are in line with our findings and conclusions. TXA is not recommended for on-demand treatment or prophylaxis. This is particularly relevant in Japan, considering that alongside danazol, TXA is the only other option available for LTP.
Neither treatment can be considered both safe and effective in the majority of patients with HAE. As such, these findings highlight a significant unmet need in Japan with regard to the paucity of clinically effective treatment options, and suggest the need for increased awareness among patients and physicians to ensure more options become available in the near future. The use of TXA is advocated in selected patients that have already been shown to benefit; however, it is likely that once more options become more widely available, the requirement for TXA in both on-demand and prophylactic treatment of HAE may be significantly reduced.
There are several limitations to this review, not least the lack of robust quantitative data generated from well-conducted RCTs.
A large number of studies, particularly in prophylaxis, failed to report numerical data, stating only that TXA was either effective or ineffective at reducing symptoms and/or the frequency of attacks. 37, 39, 41, 49, 50, 57 Data generated from observational studies and case reports are inherently biased due to the lack of comparators and lack of control over confounding variables; these issues are much less likely to arise in RCTs. Finally, many studies did not report any safety data, which makes it difficult to draw firm conclusions regarding the safety of TXA in the HAE patient population.
The findings presented in this review highlight several conclusions. TXA may be more effective than no treatment, particularly for STP. However, the efficacy of TXA varies widely between patients, and in many cases, the effect of TXA is negligible. there may be limited utility for TXA in STP prior to dental procedures and minor surgery; however, where available, newer, more effective therapies should be used in place of TXA for LTP.
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